{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:55:13Z","timestamp":1790668513484,"version":"4.1.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04425-w","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:35:09Z","timestamp":1784536509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9826-3137","authenticated-orcid":false,"given":"Duc-Hiep","family":"Bach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van T.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pham Thi Viet","family":"Huong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinh Duy","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh Liem","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"5","key":"4425_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"26","key":"4425_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"19","key":"4425_CR3","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141(19):2307\u201315.","journal-title":"Blood"},{"issue":"4","key":"4425_CR4","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/d41573-024-00035-1","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard A. FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers. Nat Rev Drug Discov. 2024;23(4):238.","journal-title":"Nat Rev Drug Discov"},{"issue":"24","key":"4425_CR5","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC, Whitman ED, et al. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021;39(24):2656\u201366.","journal-title":"J Clin Oncol"},{"issue":"23","key":"4425_CR6","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Borch TH, Berg JHvd, Met \u00d6, Kessels R, Foppen MHG, Granh\u00f8j JS, Nuijen B, Nijenhuis C, Jedema I, et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med. 2022;387(23):2113\u201325.","journal-title":"N Engl J Med"},{"issue":"5","key":"4425_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350.","journal-title":"Nat Med"},{"issue":"6230","key":"4425_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74\u201380.","journal-title":"Science"},{"issue":"7693","key":"4425_CR9","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel Iii EE, Koeppen H, Astarita JL, Cubas R, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138.","journal-title":"Nature"},{"issue":"4","key":"4425_CR10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Swanton C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017;168(4):613\u201328.","journal-title":"Cell"},{"issue":"9","key":"4425_CR11","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016;375(9):819\u201329.","journal-title":"N Engl J Med"},{"issue":"8","key":"4425_CR12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"4425_CR13","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015;162(6):1229\u201341.","journal-title":"Cell"},{"issue":"4","key":"4425_CR14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253\u201368.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"4425_CR15","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, McNamara KL, Granja JM, Sarin KY, Brown RA, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019;25(8):1251\u20139.","journal-title":"Nat Med"},{"issue":"4","key":"4425_CR16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Mart\u00edn-Algarra S, Mandal R, Sharfman WH, et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017;171(4):934\u2013e949916.","journal-title":"Cell"},{"issue":"3","key":"4425_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discovery. 2019;18(3):197\u2013218.","journal-title":"Nat Rev Drug Discovery"},{"issue":"8","key":"4425_CR18","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145\u201354.","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"4425_CR19","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, et al. Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape. J Clin Invest. 2016;126(8):3036\u201352.","journal-title":"J Clin Invest"},{"issue":"2","key":"4425_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, Walker WJ, McNally KA, Lim WA. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell. 2016;167(2):419\u2013e432416.","journal-title":"Cell"},{"issue":"4","key":"4425_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36(4):346\u201351.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"4425_CR22","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1038\/mtna.2013.32","volume":"2","author":"Z Grada","year":"2013","unstructured":"Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Sch\u00f6nfeld K, Koch J, Dotti G, et al. TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Mol Ther Nucleic Acids. 2013;2(7):e105.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6481","key":"4425_CR23","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365.","journal-title":"Science"},{"issue":"1","key":"4425_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"S Chen Daniel","year":"2013","unstructured":"Chen Daniel S, Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity. 2013;39(1):1\u201310.","journal-title":"Immunity"},{"issue":"10","key":"4425_CR25","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity. 2023;56(10):2188\u2013205.","journal-title":"Immunity"},{"key":"4425_CR26","doi-asserted-by":"publisher","first-page":"773420","DOI":"10.3389\/fonc.2021.773420","volume":"11","author":"SK Von Rueden","year":"2021","unstructured":"Von Rueden SK, Fan TM. Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer. Front Oncol. 2021;11:773420.","journal-title":"Front Oncol"},{"issue":"10","key":"4425_CR27","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.immuni.2023.09.010","volume":"56","author":"N Singh","year":"2023","unstructured":"Singh N, Maus MV. Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy. Immunity. 2023;56(10):2296\u2013310.","journal-title":"Immunity"},{"issue":"5","key":"4425_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Reviews Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"7649","key":"4425_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nature21724","volume":"544","author":"L Tian","year":"2017","unstructured":"Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, Sheng K, Dobrolecki LE, Zhang X, Putluri N, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544(7649):250\u20134.","journal-title":"Nature"},{"issue":"8","key":"4425_CR30","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00262-017-2003-1","volume":"66","author":"H Jiang","year":"2017","unstructured":"Jiang H, Hegde S, DeNardo DG. Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. Cancer Immunol Immunother. 2017;66(8):1037\u201348.","journal-title":"Cancer Immunol Immunother"},{"key":"4425_CR31","doi-asserted-by":"crossref","unstructured":"Feig C, Jones JO, Kraman M, Wells RJB, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti\u2013PD-L1 immunotherapy in pancreatic cancer. Proceedings of the National Academy of Sciences 2013, 110(50):20212\u201320217.","DOI":"10.1073\/pnas.1320318110"},{"issue":"5","key":"4425_CR32","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D, Dotti G. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21(5):524\u20139.","journal-title":"Nat Med"},{"issue":"9","key":"4425_CR33","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559\u201372.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"4425_CR34","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/eji.201948457","volume":"50","author":"G Liu","year":"2020","unstructured":"Liu G, Rui W, Zheng H, Huang D, Yu F, Zhang Y, Dong J, Zhao X, Lin X. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur J Immunol. 2020;50(5):712\u201324.","journal-title":"Eur J Immunol"},{"issue":"26","key":"4425_CR35","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016;375(26):2561\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"4425_CR36","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1172\/JCI46102","volume":"121","author":"L Baitsch","year":"2011","unstructured":"Baitsch L, Baumgaertner P, Dev\u00eavre E, Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplancke B, Romero P, et al. Exhaustion of tumor-specific CD8\u207a T cells in metastases from melanoma patients. J Clin Invest. 2011;121(6):2350\u201360.","journal-title":"J Clin Invest"},{"issue":"4","key":"4425_CR37","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018;175(4):998\u2013e10131020.","journal-title":"Cell"},{"issue":"7528","key":"4425_CR38","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"issue":"3","key":"4425_CR39","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","volume":"7","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov. 2017;7(3):264\u201376.","journal-title":"Cancer Discov"},{"issue":"4","key":"4425_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223\u201338.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"4425_CR41","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41590-020-0760-z","volume":"21","author":"DT Utzschneider","year":"2020","unstructured":"Utzschneider DT, Gabriel SS, Chisanga D, Gloury R, Gubser PM, Vasanthakumar A, Shi W, Kallies A. Early precursor T cells establish and propagate T cell exhaustion in chronic infection. Nat Immunol. 2020;21(10):1256\u201366.","journal-title":"Nat Immunol"},{"key":"4425_CR42","doi-asserted-by":"publisher","first-page":"105240","DOI":"10.1016\/j.ebiom.2024.105240","volume":"106","author":"J Mietz","year":"2024","unstructured":"Mietz J, Kaulfuss M, Egli L, Opitz L, M\u00fcnz C, Chijioke O. Human effector CD8(+) T cells with an activated and exhausted-like phenotype control tumour growth in vivo in a humanized tumour model. EBioMedicine. 2024;106:105240.","journal-title":"EBioMedicine"},{"issue":"1","key":"4425_CR43","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-023-01504-7","volume":"16","author":"Y Bulliard","year":"2023","unstructured":"Bulliard Y, Andersson BS, Baysal MA, Damiano J, Tsimberidou AM. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy. J Hematol Oncol. 2023;16(1):108.","journal-title":"J Hematol Oncol"},{"issue":"8059","key":"4425_CR44","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/s41586-024-08451-4","volume":"640","author":"T Chu","year":"2025","unstructured":"Chu T, Wu M, Hoellbacher B, de Almeida GP, Wurmser C, Berner J, Donhauser LV, Gerullis A-K, Lin S, Cepeda-Mayorga JD, et al. Precursors of exhausted T cells are pre-emptively formed in acute infection. Nature. 2025;640(8059):782\u201392.","journal-title":"Nature"},{"issue":"8","key":"4425_CR45","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41577-019-0193-9","volume":"19","author":"Y Bordon","year":"2019","unstructured":"Bordon Y. TOX for tired T cells. Nat Rev Immunol. 2019;19(8):476\u2013476.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"4425_CR46","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41590-022-01219-w","volume":"23","author":"D Zehn","year":"2022","unstructured":"Zehn D, Thimme R, Lugli E, de Almeida GP, Oxenius A. Stem-like\u2019 precursors are the fount to sustain persistent CD8\u2009+\u2009T cell responses. Nat Immunol. 2022;23(6):836\u201347.","journal-title":"Nat Immunol"},{"issue":"12","key":"4425_CR47","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol. 2022;19(12):775\u201390.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4425_CR48","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"OO Yeku","year":"2017","unstructured":"Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017;7(1):10541.","journal-title":"Sci Rep"},{"issue":"1","key":"4425_CR49","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4049\/jimmunol.1800033","volume":"203","author":"Y Liu","year":"2019","unstructured":"Liu Y, Di S, Shi B, Zhang H, Wang Y, Wu X, Luo H, Wang H, Li Z, Jiang H. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma. J Immunol. 2019;203(1):198\u2013207.","journal-title":"J Immunol"},{"issue":"6","key":"4425_CR50","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581\u201390.","journal-title":"Nat Med"},{"issue":"1","key":"4425_CR51","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc1782","volume":"6","author":"KE de Visser","year":"2006","unstructured":"de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6(1):24\u201337.","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"4425_CR52","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG. CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057\u201369.","journal-title":"Cancer Res"},{"issue":"10","key":"4425_CR53","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1016\/j.ymthe.2024.09.015","volume":"32","author":"N Singh","year":"2024","unstructured":"Singh N. Approval of the first TCR-based cell therapy. Mol Ther. 2024;32(10):3195.","journal-title":"Mol Ther"},{"issue":"16suppl","key":"4425_CR54","doi-asserted-by":"publisher","first-page":"9519","DOI":"10.1200\/JCO.2025.43.16_suppl.9519","volume":"43","author":"RN Amaria","year":"2025","unstructured":"Amaria RN, Diab A, Tawbi HA, Glitza IC, McQuade JL, Davies MA, Ikeguchi A, Wong MKK, Patel SP, Bassett RL, et al. OBX-115 engineered tumor-infiltrating lymphocytes (TIL) with regulatable membrane-bound IL15 (mbIL15): Translational data from a single-center phase 1 trial in patients (pts) with immune checkpoint inhibitor (ICI)\u2013resistant advanced melanoma. J Clin Oncol. 2025;43(16suppl):9519\u20139519.","journal-title":"J Clin Oncol"},{"issue":"10494","key":"4425_CR55","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi C, Liu C, Peng Z, Zhang Y, Wei J, Qiu W, Zhang X, Pan H, Niu Z, Qiu M, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025;405(10494):2049\u201360.","journal-title":"Lancet"},{"issue":"16suppl","key":"4425_CR56","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2025.43.16_suppl.4003","volume":"43","author":"C Qi","year":"2025","unstructured":"Qi C, Liu C, Peng Z, Zhang Y, Wei J, Qiu W, Zhang X, Pan H, Niu Z, Qiu M, et al. Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician\u2019s choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G\/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01). J Clin Oncol. 2025;43(16suppl):4003\u20134003.","journal-title":"J Clin Oncol"},{"issue":"8046","key":"4425_CR57","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje M, Mahdi J, Majzner R, Yeom KW, Schultz LM, Richards RM, Barsan V, Song K-W, Kamens J, Baggott C, et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature. 2025;637(8046):708\u201315.","journal-title":"Nature"},{"key":"4425_CR58","doi-asserted-by":"crossref","unstructured":"Foster JB, Madsen PJ, Harvey K, Griffin C, Stern A, Patterson L, Joshi N, Dickson C, McManus O, Beaubien E et al. Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models. Neuro-Oncology 2025.","DOI":"10.1093\/neuonc\/noaf115"},{"issue":"8","key":"4425_CR59","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","volume":"31","author":"SJ Bagley","year":"2025","unstructured":"Bagley SJ, Desai AS, Fraietta JA, Silverbush D, Chafamo D, Freeburg NF, Gopikrishna GK, Rech AJ, Nabavizadeh A, Bagley LJ, et al. Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial. Nat Med. 2025;31(8):2778\u201387.","journal-title":"Nat Med"},{"issue":"8","key":"4425_CR60","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","volume":"14","author":"AJ Schoenfeld","year":"2024","unstructured":"Schoenfeld AJ, Lee SM, Doger de Sp\u00e9ville B, Gettinger SN, H\u00e4fliger S, Sukari A, Papa S, Rodr\u00edguez-Moreno JF, Graf Finckenstein F, Fiaz R, et al. Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. Cancer Discov. 2024;14(8):1389\u2013402.","journal-title":"Cancer Discov"},{"issue":"23","key":"4425_CR61","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Borch TH, van den Berg JH, Met \u00d6, Kessels R, Geukes Foppen MH, Stoltenborg Granh\u00f8j J, Nuijen B, Nijenhuis C, Jedema I, et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med. 2022;387(23):2113\u201325.","journal-title":"N Engl J Med"},{"issue":"8","key":"4425_CR62","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021;27(8):1410\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"4425_CR63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s44178-024-00113-9","volume":"4","author":"J Liu","year":"2025","unstructured":"Liu J, Kang Y, Li L, Zang L, Luo L, Zhu F, Zhu M, Zhang H, Xu Q. Efficacy and safety of immunotherapy in cervical cancer: a review of advances in immune-related therapy for cervical cancer. Holist Integr Oncol. 2025;4(1):15.","journal-title":"Holist Integr Oncol"},{"issue":"10","key":"4425_CR64","doi-asserted-by":"publisher","first-page":"S1012","DOI":"10.1016\/j.jtho.2021.08.335","volume":"16","author":"S Gettinger","year":"2021","unstructured":"Gettinger S, Kluger H, Schoenfeld A, Warner AB, He K, Sukari A, Thomas S, Doger B, Lee S, Haefliger S, et al. P14.05 Phase 2, Study of Iovance Autologous Tumor Infiltrating Lymphocytes (Lifileucel, LN-144, LN-145, LN-145-S1) In Patients With Solid Tumors. J Thorac Oncol. 2021;16(10):S1012\u20133.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"4425_CR65","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I, Solomon SB, Rusch VW, O\u2019Cearbhaill RE, Zhu A, Cheema W, Chintala NK, Halton E, et al. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. Cancer Discov. 2021;11(11):2748\u201363.","journal-title":"Cancer Discov"},{"issue":"11","key":"4425_CR66","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","volume":"27","author":"AR Haas","year":"2019","unstructured":"Haas AR, Tanyi JL, O\u2019Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, et al. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Mol Ther. 2019;27(11):1919\u201329.","journal-title":"Mol Ther"},{"issue":"399","key":"4425_CR67","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984.","journal-title":"Sci Transl Med"},{"issue":"7903","key":"4425_CR68","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V, Mancusi R, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603(7903):934\u201341.","journal-title":"Nature"},{"issue":"4","key":"4425_CR69","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843\u201351.","journal-title":"Mol Ther"},{"issue":"6","key":"4425_CR70","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28(6):1189\u201398.","journal-title":"Nat Med"},{"issue":"5","key":"4425_CR71","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s43018-025-00946-x","volume":"6","author":"C Wang","year":"2025","unstructured":"Wang C, Yu X, Teer JK, Yao J, Du D, Liu X, Thompson ZJ, Wang MH, Welsh EA, Memon D, et al. Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy. Nat Cancer. 2025;6(5):801\u201319.","journal-title":"Nat Cancer"},{"issue":"5594","key":"4425_CR72","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1076514","volume":"298","author":"ME Dudley","year":"2002","unstructured":"Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850\u20134.","journal-title":"Science"},{"issue":"17","key":"4425_CR73","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","volume":"75","author":"X Liu","year":"2015","unstructured":"Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, Cogdill AP, Li N, Ramones M, Granda B, et al. Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Res. 2015;75(17):3596\u2013607.","journal-title":"Cancer Res"},{"issue":"6334","key":"4425_CR74","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1126\/science.aak9510","volume":"356","author":"S Stevanovi\u0107","year":"2017","unstructured":"Stevanovi\u0107 S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017;356(6334):200\u20135.","journal-title":"Science"},{"issue":"1","key":"4425_CR75","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","volume":"24","author":"SJ Priceman","year":"2018","unstructured":"Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, Chang W-C, Ostberg JR, Neman J, Jandial R, et al. Regional Delivery of Chimeric Antigen Receptor\u2013Engineered T Cells Effectively Targets HER2\u2009+\u2009Breast Cancer Metastasis to the Brain. Clin Cancer Res. 2018;24(1):95\u2013105.","journal-title":"Clin Cancer Res"},{"key":"4425_CR76","doi-asserted-by":"crossref","unstructured":"Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, Mades A, Sadelain M, Einsele H, Hudecek M. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci Transl Med 2019, 11(499).","DOI":"10.1126\/scitranslmed.aau5907"},{"issue":"2","key":"4425_CR77","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","volume":"40","author":"M Poorebrahim","year":"2021","unstructured":"Poorebrahim M, Melief J, Pico de Coa\u00f1a Y, Wickstr\u00f6m L, Cid-Arregui S, Kiessling A. Counteracting CAR T cell dysfunction. Oncogene. 2021;40(2):421\u201335.","journal-title":"Oncogene"},{"key":"4425_CR78","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.omto.2017.12.003","volume":"8","author":"G Kueberuwa","year":"2018","unstructured":"Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins RE, Gilham DE. CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity. Mol Ther Oncolytics. 2018;8:41\u201351.","journal-title":"Mol Ther Oncolytics"},{"issue":"11","key":"4425_CR79","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","volume":"36","author":"CM Bollard","year":"2018","unstructured":"Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, et al. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018;36(11):1128\u201339.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4425_CR80","first-page":"4038","volume":"10","author":"J Jin","year":"2020","unstructured":"Jin J, Cheng J, Huang M, Luo H, Zhou J. Fueling chimeric antigen receptor T cells with cytokines. Am J Cancer Res. 2020;10(12):4038\u201355.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"4425_CR81","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","volume":"45","author":"NE Scharping","year":"2016","unstructured":"Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris RL, Delgoffe GM. The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. Immunity. 2016;45(2):374\u201388.","journal-title":"Immunity"},{"issue":"10","key":"4425_CR82","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290\u20137.","journal-title":"Nat Med"},{"issue":"10","key":"4425_CR83","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41587-022-01384-1","volume":"40","author":"SC Oostindie","year":"2022","unstructured":"Oostindie SC, Rinaldi DA, Zom GG, Wester MJ, Paulet D, Al-Tamimi K, van der Meijden E, Scheick JR, Wilpshaar T, de Jong B, et al. Logic-gated antibody pairs that selectively act on cells co-expressing two antigens. Nat Biotechnol. 2022;40(10):1509\u201319.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"4425_CR84","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"T Roybal Kole","year":"2016","unstructured":"Roybal Kole T, Rupp Levi J, Morsut L, Walker Whitney J, McNally Krista A, Park Jason S. Lim Wendell A: Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. Cell. 2016;164(4):770\u20139.","journal-title":"Cell"},{"issue":"11","key":"4425_CR85","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.cels.2022.09.006","volume":"13","author":"S Lee","year":"2022","unstructured":"Lee S, Khalil AS, Wong WW. Recent progress of gene circuit designs in immune cell therapies. Cell Syst. 2022;13(11):864\u201373.","journal-title":"Cell Syst"},{"issue":"1","key":"4425_CR86","doi-asserted-by":"publisher","first-page":"1785608","DOI":"10.1080\/2162402X.2020.1785608","volume":"9","author":"A Feldmann","year":"2020","unstructured":"Feldmann A, Hoffmann A, Bergmann R, Koristka S, Berndt N, Arndt C, Rodrigues Loureiro L, Kittel-Boselli E, Mitwasi N, Kegler A, et al. Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy. Oncoimmunology. 2020;9(1):1785608.","journal-title":"Oncoimmunology"},{"key":"4425_CR87","doi-asserted-by":"crossref","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F et al. CRISPR-engineered T cells in patients with refractory cancer. Science 2020, 367(6481).","DOI":"10.1126\/science.aba7365"},{"issue":"6","key":"4425_CR88","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","volume":"174","author":"L Keren","year":"2018","unstructured":"Keren L, Bosse M, Marquez D, Angoshtari R, Jain S, Varma S, Yang SR, Kurian A, Van Valen D, West R, et al. A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. Cell. 2018;174(6):1373\u2013e13871319.","journal-title":"Cell"},{"issue":"261","key":"4425_CR89","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","volume":"6","author":"PS Adusumilli","year":"2014","unstructured":"Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014;6(261):261ra151.","journal-title":"Sci Transl Med"},{"issue":"14","key":"4425_CR90","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","volume":"21","author":"SC Katz","year":"2015","unstructured":"Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, Khare PD, Thorn M, Ma Q, Stainken BF, et al. Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases. Clin Cancer Res. 2015;21(14):3149\u201359.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4425_CR91","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S1055-3207(03)00080-2","volume":"11","author":"MI D\u2019Angelica","year":"2002","unstructured":"D\u2019Angelica MI, Shoup MC, Nissan A. Randomized Clinical Trials in Advanced and Metastatic Colorectal Carcinoma. Surg Oncol Clin N Am. 2002;11(1):173\u201391.","journal-title":"Surg Oncol Clin N Am"},{"issue":"10","key":"4425_CR92","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","volume":"29","author":"A Betof Warner","year":"2023","unstructured":"Betof Warner A, Corrie PG, Hamid O. Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future. Clin Cancer Res. 2023;29(10):1835\u201354.","journal-title":"Clin Cancer Res"},{"key":"4425_CR93","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fonc.2019.00196","volume":"9","author":"S Patel","year":"2019","unstructured":"Patel S, Burga RA, Powell AB, Chorvinsky EA, Hoq N, McCormack SE, Van Pelt SN, Hanley PJ, Cruz CRY. Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer. Front Oncol. 2019;9:196.","journal-title":"Front Oncol"},{"issue":"6522","key":"4425_CR94","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1126\/science.abb9847","volume":"370","author":"S Krishna","year":"2020","unstructured":"Krishna S, Lowery FJ, Copeland AR, Bahadiroglu E, Mukherjee R, Jia L, Anibal JT, Sachs A, Adebola SO, Gurusamy D, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science. 2020;370(6522):1328\u201334.","journal-title":"Science"},{"key":"4425_CR95","doi-asserted-by":"crossref","unstructured":"Vaishampayan UN, Muzaffar J, Winer I, Rosen SD, Hoimes CJ, Chauhan A, Spreafico A, Lewis KD, Bruno DS, Dumas O et al. Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1). J Immunother Cancer 2024, 12(11).","DOI":"10.1136\/jitc-2024-010143"},{"key":"4425_CR96","doi-asserted-by":"publisher","first-page":"110358","DOI":"10.1016\/j.intimp.2023.110358","volume":"120","author":"J Zhao","year":"2023","unstructured":"Zhao J, Li L, Yin H, Feng X, Lu Q. TIGIT: An emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer. Int Immunopharmacol. 2023;120:110358.","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"4425_CR97","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","volume":"24","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023;24(9):1415\u201322.","journal-title":"Nat Immunol"},{"issue":"6","key":"4425_CR98","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","volume":"2","author":"S Demaria","year":"2016","unstructured":"Demaria S, Coleman CN, Formenti SC. Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer. 2016;2(6):286\u201394.","journal-title":"Trends Cancer"},{"issue":"6","key":"4425_CR99","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170(6):1109\u2013e11191110.","journal-title":"Cell"},{"issue":"2","key":"4425_CR100","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1158\/1078-0432.CCR-12-1626","volume":"19","author":"C Liu","year":"2013","unstructured":"Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013;19(2):393\u2013403.","journal-title":"Clin Cancer Res"},{"issue":"5706","key":"4425_CR101","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58\u201362.","journal-title":"Science"},{"key":"4425_CR102","doi-asserted-by":"crossref","unstructured":"Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proceedings of the National Academy of Sciences 2012, 109(43):17561\u201317566.","DOI":"10.1073\/pnas.1215397109"},{"issue":"10","key":"4425_CR103","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264\u201372.","journal-title":"Nat Med"},{"issue":"7693","key":"4425_CR104","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138.","journal-title":"Nature"},{"issue":"10135","key":"4425_CR105","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","volume":"391","author":"F Pag\u00e8s","year":"2018","unstructured":"Pag\u00e8s F, Mlecnik B, Marliot F, Bindea G, Ou F-S, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128\u201339.","journal-title":"Lancet"},{"issue":"6280","key":"4425_CR106","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463\u20139.","journal-title":"Science"},{"issue":"6286","key":"4425_CR107","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1126\/science.aaf2834","volume":"352","author":"CU Blank","year":"2016","unstructured":"Blank CU, Haanen JB, Ribas A, Schumacher TN. CANCER IMMUNOLOGY. The cancer immunogram. Science. 2016;352(6286):658\u201360.","journal-title":"Science"},{"issue":"7637","key":"4425_CR108","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"key":"4425_CR109","first-page":"101290","volume":"53","author":"S Ogino","year":"2026","unstructured":"Ogino S, Patel AV, Ugai S, Giannakis M, Ugai T. Unique role of the prospective cohort incident-tumor biobank method in etiological research. Lancet Reg Health Am. 2026;53:101290.","journal-title":"Lancet Reg Health Am"},{"issue":"3","key":"4425_CR110","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41379-018-0142-3","volume":"32","author":"H Kim","year":"2019","unstructured":"Kim H, Kwon HJ, Han YB, Park SY, Kim ES, Kim SH, Kim YJ, Lee JS, Chung J-H. Increased CD3\u2009+\u2009T cells with a low FOXP3+\/CD8\u2009+\u2009T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients. Mod Pathol. 2019;32(3):367\u201375.","journal-title":"Mod Pathol"},{"issue":"1","key":"4425_CR111","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41467-023-36325-2","volume":"14","author":"T Hirz","year":"2023","unstructured":"Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, Subtelny AO, Zlatev DV, Wszolek MW, Salari K, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14(1):663.","journal-title":"Nat Commun"},{"key":"4425_CR112","doi-asserted-by":"publisher","first-page":"1568590","DOI":"10.3389\/fimmu.2025.1568590","volume":"16","author":"SW Choi","year":"2025","unstructured":"Choi SW, Kim JH, Hong J, Kwon M. Mapping immunotherapy potential: spatial transcriptomics in the unraveling of tumor-immune microenvironments in head and neck squamous cell carcinoma. Front Immunol. 2025;16:1568590.","journal-title":"Front Immunol"},{"issue":"5","key":"4425_CR113","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s43018-023-00547-6","volume":"4","author":"L van Hooren","year":"2023","unstructured":"van Hooren L, Handgraaf SM, Kloosterman DJ, Karimi E, van Mil LWHG, Gassama AA, Solsona BG, de Groot MHP, Brandsma D, Quail DF, et al. CD103\u2009+\u2009regulatory T cells underlie resistance to radio-immunotherapy and impair CD8\u2009+\u2009T cell activation in glioblastoma. Nat Cancer. 2023;4(5):665\u201381.","journal-title":"Nat Cancer"},{"key":"4425_CR114","doi-asserted-by":"crossref","unstructured":"Taube JM, Akturk G, Angelo M, Engle EL, Gnjatic S, Greenbaum S, Greenwald NF, Hedvat CV, Hollmann TJ, Juco J et al. The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. J Immunother Cancer 2020, 8(1).","DOI":"10.1136\/jitc-2019-000155"},{"issue":"1","key":"4425_CR115","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41592-020-01033-y","volume":"18","author":"V Marx","year":"2021","unstructured":"Marx V. Method of the Year: spatially resolved transcriptomics. Nat Methods. 2021;18(1):9\u201314.","journal-title":"Nat Methods"},{"issue":"6411","key":"4425_CR116","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy. Science. 2018;362(6411):eaar3593.","journal-title":"Science"},{"issue":"3","key":"4425_CR117","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrclinonc.2016.162","volume":"14","author":"JPB O\u2019Connor","year":"2017","unstructured":"O\u2019Connor JPB, Aboagye EO, Adams JE, Aerts HJWL, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, et al. Imaging biomarker roadmap for cancer studies. Nat Reviews Clin Oncol. 2017;14(3):169\u201386.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"12","key":"4425_CR118","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/s41591-022-02084-8","volume":"28","author":"L Kist de Ruijter","year":"2022","unstructured":"Kist de Ruijter L, van de Donk PP, Hooiveld-Noeken JS, Giesen D, Elias SG, Lub-de Hooge MN, Oosting SF, Jalving M, Timens W, Brouwers AH, et al. Whole-body CD8\u2009+\u2009T cell visualization before and during cancer immunotherapy: a phase 1\/2 trial. Nat Med. 2022;28(12):2601\u201310.","journal-title":"Nat Med"},{"issue":"1","key":"4425_CR119","doi-asserted-by":"publisher","first-page":"8791","DOI":"10.1038\/s41467-024-53197-2","volume":"15","author":"X Shen","year":"2024","unstructured":"Shen X, Zhou H, Zhou X, Liu Z, Meng X, Zhang L, Song Y, Guo R, Wang F, Li K, et al. 68Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1\/2 clinical trial. Nat Commun. 2024;15(1):8791.","journal-title":"Nat Commun"},{"issue":"1","key":"4425_CR120","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021;27(1):152\u201364.","journal-title":"Nat Med"},{"issue":"5","key":"4425_CR121","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, Myklebust JH, Kadapakkam M, Weber EW, Tousley AM, et al. Tuning the Antigen Density Requirement for CAR T-cell Activity. Cancer Discov. 2020;10(5):702\u201323.","journal-title":"Cancer Discov"},{"issue":"4","key":"4425_CR122","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh M, Mansilla-Soto J, Rivi\u00e8re I, Sadelain M. Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating. Cancer Discov. 2023;13(4):829\u201343.","journal-title":"Cancer Discov"},{"issue":"4","key":"4425_CR123","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.2869","volume":"11","author":"C Giesen","year":"2014","unstructured":"Giesen C, Wang HA, Schapiro D, Zivanovic N, Jacobs A, Hattendorf B, Sch\u00fcffler PJ, Grolimund D, Buhmann JM, Brandt S, et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods. 2014;11(4):417\u201322.","journal-title":"Nat Methods"},{"issue":"6","key":"4425_CR124","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017;171(6):1259\u2013e12711211.","journal-title":"Cell"},{"issue":"2","key":"4425_CR125","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s43018-019-0011-0","volume":"1","author":"EJ Moding","year":"2020","unstructured":"Moding EJ, Liu Y, Nabet BY, Chabon JJ, Chaudhuri AA, Hui AB, Bonilla RF, Ko RB, Yoo CH, Gojenola L, et al. Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. Nat Cancer. 2020;1(2):176\u201383.","journal-title":"Nat Cancer"},{"issue":"13","key":"4425_CR126","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","volume":"22","author":"E Sanchez","year":"2016","unstructured":"Sanchez E, Gillespie A, Tang G, Ferros M, Harutyunyan NM, Vardanyan S, Gottlieb J, Li M, Wang CS, Chen H, et al. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma. Clin Cancer Res. 2016;22(13):3383\u201397.","journal-title":"Clin Cancer Res"},{"issue":"6286","key":"4425_CR127","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1126\/science.aaf2834","volume":"352","author":"CU Blank","year":"2016","unstructured":"Blank CU, Haanen JB, Ribas A, Schumacher TN. The cancer immunogram. Science. 2016;352(6286):658\u201360.","journal-title":"Science"},{"issue":"3","key":"4425_CR128","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"issue":"6280","key":"4425_CR129","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463\u20139.","journal-title":"Science"},{"issue":"9","key":"4425_CR130","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41551-023-01048-8","volume":"7","author":"AQ Zhang","year":"2023","unstructured":"Zhang AQ, Hostetler A, Chen LE, Mukkamala V, Abraham W, Padilla LT, Wolff AN, Maiorino L, Backlund CM, Aung A, et al. Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR. Nat Biomedical Eng. 2023;7(9):1113\u201328.","journal-title":"Nat Biomedical Eng"},{"issue":"1","key":"4425_CR131","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1158\/2159-8290.CD-17-0395","volume":"8","author":"E Pectasides","year":"2018","unstructured":"Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, et al. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018;8(1):37\u201348.","journal-title":"Cancer Discov"},{"issue":"9","key":"4425_CR132","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jtho.2020.04.026","volume":"15","author":"L Hong","year":"2020","unstructured":"Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, et al. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020;15(9):1449\u201359.","journal-title":"J Thorac Oncol"},{"issue":"7643","key":"4425_CR133","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJC, Hamieh M, Cunanan KM, Odak A, G\u00f6nen M, Sadelain M. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113\u20137.","journal-title":"Nature"},{"issue":"1","key":"4425_CR134","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386(1):24\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"4425_CR135","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1038\/s41467-023-40115-1","volume":"14","author":"EHJ Lee","year":"2023","unstructured":"Lee EHJ, Murad JP, Christian L, Gibson J, Yamaguchi Y, Cullen C, Gumber D, Park AK, Young C, Monroy I, et al. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting. Nat Commun. 2023;14(1):4737.","journal-title":"Nat Commun"},{"issue":"11","key":"4425_CR136","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Pul\u00e8 MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM, Rooney CM. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105(11):4247\u201354.","journal-title":"Blood"},{"issue":"10","key":"4425_CR137","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","volume":"29","author":"V Anagnostou","year":"2023","unstructured":"Anagnostou V, Ho C, Nicholas G, Juergens RA, Sacher A, Fung AS, Wheatley-Price P, Laurie SA, Levy B, Brahmer JR, et al. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nat Med. 2023;29(10):2559\u201369.","journal-title":"Nat Med"},{"issue":"5","key":"4425_CR138","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O\u2019Connor RS, Hwang WT, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563\u201371.","journal-title":"Nat Med"},{"issue":"9","key":"4425_CR139","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1111\/bcp.14281","volume":"86","author":"N Dasyam","year":"2020","unstructured":"Dasyam N, George P, Weinkove R. Chimeric antigen receptor T-cell therapies: Optimising the dose. Br J Clin Pharmacol. 2020;86(9):1678\u201389.","journal-title":"Br J Clin Pharmacol"},{"issue":"18","key":"4425_CR140","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;380(18):1726\u201337.","journal-title":"N Engl J Med"},{"issue":"3","key":"4425_CR141","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Liti\u00e8re S, Dancey J, Chen A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143\u201352.","journal-title":"Lancet Oncol"},{"issue":"8","key":"4425_CR142","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930\u201340.","journal-title":"J Clin Invest"},{"issue":"1","key":"4425_CR143","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"4425_CR144","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"4425_CR145","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Nikiforow S, Carter BS, Curry WT, Gallagher K, et al. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. N Engl J Med. 2024;390(14):1290\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"4425_CR146","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, Lim WA. Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. Cell. 2016;164(4):770\u20139.","journal-title":"Cell"},{"issue":"5","key":"4425_CR147","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","volume":"3","author":"EW Weber","year":"2019","unstructured":"Weber EW, Lynn RC, Sotillo E, Lattin J, Xu P, Mackall CL. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv. 2019;3(5):711\u20137.","journal-title":"Blood Adv"},{"issue":"18","key":"4425_CR148","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673\u201383.","journal-title":"N Engl J Med"},{"issue":"14","key":"4425_CR149","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, et al. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med. 2023;388(14):1284\u201395.","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1186\/s12935-026-04464-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000}}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04425-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04425-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04425-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:02:18Z","timestamp":1790665338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04425-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":149,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4425"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04425-w","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The Author group information has been updated in the article.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12935-026-04464-3","URL":"https:\/\/doi.org\/10.1186\/s12935-026-04464-3","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This review synthesizes previously published studies and did not involve new studies with human participants or animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.-H.B. used ChatGPT (OpenAI) and Gemini (Google) as language-support tools during manuscript preparation to assist with organization and clarity. These tools were also used to generate preliminary conceptual figure drafts based on the authors\u2019 scientific descriptions. They were not used as sources of scientific authority. All hypotheses, interpretations, references, and conclusions were independently developed and verified by the authors, who take full responsibility for the content of the manuscript.","order":4,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"302"}}